New Reference: Camrelizumab with Chemotherapy for Advanced Nasopharyngeal Carcinoma

The addition of camrelizumab to chemotherapy provided significant improvement in overall survival in patients with recurrent or metastatic nasopharyngeal carcinoma. The trial demonstrated a median overall survival of 34.5 months compared to 26.6 months with chemotherapy alone, establishing camrelizumab as a standard of care in this setting.

Study

Randomized, double-blind, placebo-controlled, phase 3 trial [CAPTAIN-1st]

Patients with treatment-naive recurrent or metastatic nasopharyngeal carcinoma

Camrelizumab plus CISplatin-gemcitabine (n=134) vs placebo plus CISplatin-gemcitabine (n=129)

Efficacy

mOS: 34.5 mos vs 26.6 mos (HR 0.74 [0.55-0.99])

5-yr OS: 37.8% vs 24.2%

Safety

Grade >=3 AEs: Not reported

Treatment discontinuation due to AEs: 20 patients (15%) in camrelizumab group vs 14 patients (11%) in placebo group.

Deaths due to AEs: 4 patients (3%) in camrelizumab group vs 3 patients (2%) in placebo group.

JAMA Oncol. Published online January 29, 2026

Huang Y, Sun D, Zhou H Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma

http://doi.org/10.1001/jamaoncol.2025.6245

Reviewed by Ulas D. Bayraktar, MD on Feb 15, 2026

Back to top Drag